Navigation Links
Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
Date:12/11/2009

ients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

About Circassia

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed three fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Invesco Perpetual, Goldman Sachs and Lansdowne Partners.

    For more information please visit http://www.circassia.co.uk.

    Contacts
    Steve Harris Rob Budge
    CEO RJB Communications
    Circassia Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241


SOURCE Circassia Ltd


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
2. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
3. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
4. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
5. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
6. Apnex Medical, Inc. Raises Additional $14 Million
7. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
8. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
9. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
10. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
11. Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)...  Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is ... the securities of AMAG Pharmaceuticals Inc. ("AMAG" or ... advised to contact Peretz Bronstein or ... at info@bgandg.com or 212-697-6484. ... its officers and/or directors have violated Sections 10(b) ...
(Date:7/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4rvprn/ddimer_testing ) ... Testing Market - Global Industry Analysis, Size, Share, ... report to their offering. ... one of the fastest growing markets globally. This ... health care awareness, preference of the people for ...
(Date:7/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ... "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, ... report to their offering. ... on of assay type, therapeutic area, and geography. ... been categorized into six major segments: cAMP assays, ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Transplant Patients Represents First, Pivotal Study on a New Antiviral CMV Therapy in Stem Cell ... Over a Decade ... ... 29 ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that it completed enrollment in its pivotal,Phase ...
... be Presented at ASCO Shows Survival Benefit in Complete ... Partial Responders Compared with Chemotherapy Alone, BERKELEY ... GNTA) announced the results of long-term,followup from a Phase ... sodium) Injection, in patients with chronic,lymphocytic leukemia (CLL). With ...
Cached Medicine Technology:ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 2ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 3ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 4ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 5ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients 6Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 2Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 3Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders 4
(Date:7/27/2015)... , ... July 27, 2015 , ... ... Step One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. ... of the first things FDA investigators will look at during an inspection. ...
(Date:7/27/2015)... ... July 27, 2015 , ... On July 14, 2015, Harper’s Bazaar ... Issues,” describes common skin issues such as stretch marks , fine lines ... treat them. The treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital will be holding ... all those prospective joint-replacement patients, along with their friends and family members, to attend. ... classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct 5, Nov 2, ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing ... to its options. Already an industry leader because of its use of ... for the latest successful trends in helping people to overcome addiction and live ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... Most of the 28 million Americans living with untreated ... corrective action could result in the brain actually "forgetting" how ... , Dr. Beyer is senior vice president of HearUSA (Amex: ... hearing aids companies. , "When the brain is insufficiently stimulated ...
... Fla., Oct. 19 Blue Cross and ... statewide Medicare Advantage Regional PPO plan called BlueMedicare Regional ... offerings for Florida,s Medicare eligibles. The BlueMedicare Regional PPO ... Private Fee-for-Service, Part D and Medicare Supplement plans. , ...
... ... the world,s leading manufacturer and distributor of health testing stations and automated blood pressure ... with UnitedHealth Group,s Passport to Health and Well Being at the 2009 AARP Vegas@50+ ... ...
... ... Biodiagnostics, Inc., today announced that the U.S. Food and Drug Administration ... 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. ... and hospitals to type and screen blood. Quotient Biodiagnostics was formed ...
... CITY, Kan., Oct. 19 Premier Plastic Surgery of Kansas City, ... has redesigned its extensive website to include a separate section ... and a Plastic Surgery Blog that features breaking news on ... Society for Aesthetic Plastic Surgery, cosmetic surgery for males increased ...
... and men have opposing views on many topics, and it ... pain. According to a new survey of women and men ... leading independent health information source for women, women are more ... have a higher tolerance for pain (76% versus 32%, respectively)(1).In ...
Cached Medicine News:Health News:If Hearing Loss is Not Treated, Brain Can 'Forget' How to Hear and Understand Speech 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 2Health News:Blue Cross and Blue Shield of Florida Now Offers More Choices to Florida's Seniors 3Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 2Health News:Lifeclinic to Engage People Over 50 in Utilizing Technology and Wellness at AARP 2009 Event and Expo 3Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 2Health News:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 2Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 3Health News:Premier Plastic Surgery of Kansas City's Extended Website Provides Latest Information on Male and Female Cosmetic Surgery 4Health News:Women and Men Face Off: Who Can Stand the Pain? 2Health News:Women and Men Face Off: Who Can Stand the Pain? 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: